Drug Approval | March 12, 2022
China approves BeiGene’s tislelizumab
Tislelizumab is now approved for seven indications in China
Tislelizumab is now approved for seven indications in China
The sNDA was supported by the clinical results from cohort B of a single-arm, multi-center, pivotal study (RELIANCE study) on Carteyva in adult patients with relapsed or refractory B cell non-hodgkin lymphoma in China
APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types
The artificial cornea is 100% made of non-biological materials and require no co-implantation of donor corneas and it is an ideal option for treating patients with corneal blindness
The global multi-center phase-II clinical trial will be a 36-week, multi-center, randomized, double-blind, placebo-controlled trial, followed by a 36-week open-label extension period
ASC10 is an oral direct-acting antiviral drug candidate targeting RNA dependent RNA polymerase (RdRp) to treat SARS-CoV-2 infection
The NMPA approval is based on the positive data of GEMSTONE-302 study, a multi-center, randomized, double-blind, phase III study that evaluated the efficacy and safety of Cejemly or placebo in combination with chemotherapy in first-line stage IV NSCLC patients
Brii Bio announces amubarvimab/romlusevimab combination received approval from NMPA
The medicine is now approved for eight indications across five different types of cancer in China.
The bioequivalence study was conducted by Accutest Research India, one of the preferred CRO players in India
Subscribe To Our Newsletter & Stay Updated
